Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $1.2

Moomoo NewsNov 27 16:31 ET · Ratings

Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)

TipRanksNov 27 00:42 ET · Ratings

H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 26 10:31 ET · Ratings

Lexicon Pharmaceuticals: Strategic Focus on Promising Pipeline Amid Clinical Progress and Restructuring

TipRanksNov 26 09:45 ET

Express News | Lexicon Pharmaceuticals Inc - Top-Line Data From Progress Study Expected in Q1 2025

ReutersNov 26 08:00 ET

Express News | Lexicon Announces Completion of Enrollment in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain (Dpnp)

ReutersNov 26 08:00 ET